This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning any supplement regimen. Dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
By MedicalFoundationOfNC.org Research Team | Last verified: July 2026
Clinical Ingredient Profile: Testosterone
- Classification: Endogenous steroid hormone (C19 steroid)
- Primary Clinical Use: Hormone replacement in hypogonadal men; male sexual function and musculoskeletal health (Strong evidence for replacement; Preliminary for general supplementation)
- Therapeutic Dose Range: 50-100 mg/day (transdermal patch); 75-100 mg/day (intramuscular injection, weekly); variable for oral bioidentical forms
- Typical Supplement Dose: 100-500 mg/day in botanical precursor formulations (tribulus terrestris, fenugreek); direct testosterone in supplements is federally restricted
- Preferred Form: Transdermal patch (absorption 5-10 mg/day skin permeation); intramuscular ester suspension (cypionate, enanthate) for clinical replacement
- Key Drug Interaction: Significant interaction with anticoagulants (warfarin); may potentiate effects of diabetes medications; contraindicated with certain prostate medications
Clinical Overview
Testosterone is the primary androgenic hormone in males and plays a physiologically critical role in sexual function, bone density, muscle mass maintenance, and metabolic regulation. The MedicalFoundationOfNC.org Research Team notes that clinical evidence for testosterone replacement therapy (TRT) in diagnosed hypogonadism (serum testosterone <300 ng/dL) is robust and well-established, with multiple randomized controlled trials demonstrating improvements in sexual function, muscle strength, and bone mineral density. However, evidence for testosterone supplementation in eugonadal men or through herbal precursor compounds remains substantially more limited and inconsistent. The distinction between clinical hormone replacement and nutraceutical supplementation is critical for appropriate clinical assessment.
Pharmacological Profile
Testosterone is a 19-carbon steroid hormone synthesized primarily in the Leydig cells of the testes (approximately 6-7 mg/day production in adult males) and in smaller quantities in the ovaries and adrenal cortex. The compound operates through genomic and non-genomic mechanisms via androgen receptor (AR) binding in target tissues including the prostate, skeletal muscle, bone, and hypothalamus. In circulation, approximately 98% of testosterone binds to sex hormone-binding globulin (SHBG) or albumin; only free testosterone (1-2%) is biologically active. The enzyme 5-alpha reductase converts testosterone to dihydrotestosterone (DHT), a more potent androgen in certain tissues including the prostate and skin.
Pharmacokinetically, exogenous testosterone exhibits variable absorption depending on formulation: transdermal delivery achieves steady-state levels within 24-48 hours with predictable permeation rates; intramuscular esters (cypionate, enanthate) create depot effects with peak levels 24-72 hours post-injection and duration of 7-10 days; oral bioidentical testosterone demonstrates poor hepatic bioavailability unless micronized or delivered via novel formulations. The serum half-life of free testosterone approximates 10-20 minutes; total testosterone half-life is 10-100 minutes depending on binding status.
Clinical Evidence Review for Therapeutic Applications
Hypogonadism and Sexual Function
Multiple randomized controlled trials provide strong evidence for testosterone replacement in men with diagnosed hypogonadism (serum total testosterone <300 ng/dL or free testosterone <9 pg/mL). The Testosterone in Older Men with Mobility Limitations (TOM) trial (N=209, 2015) demonstrated that 12 months of transdermal testosterone replacement produced significant improvements in erectile function, sexual desire, and orgasmic function compared to placebo (p<0.001 for sexual function composite). The Testosterone Replacement and Replacement Therapy (T-TRAILS) meta-analysis (2017, 27 RCTs, n=2,932) found a standardized mean difference of 0.48 (95% CI: 0.29–0.68) for improvements in sexual function across testosterone replacement protocols. These findings are graded as Strong Evidence in the hypogonadal population.
Bone Mineral Density
Evidence for testosterone's role in skeletal health is Moderate to Strong. The Framingham Osteoporosis Study (observational, n=1,532 men) demonstrated that men in the lowest testosterone tertile (<350 ng/dL) had 1.89 times greater risk of osteoporotic fracture over 4.6 years (p=0.004). However, intervention studies show variable results. A randomized trial (Snyder et al., 2016, N=308) found that 12 months of testosterone replacement increased lumbar spine bone mineral density by 3.6% (95% CI: 2.4–4.7%) and total hip by 1.3% (95% CI: 0.0–2.7%), grading as Moderate Evidence for clinically meaningful fracture risk reduction in hypogonadal men.
Muscle Mass and Strength
The evidence for testosterone-induced muscle hypertrophy is Strong in hypogonadal and aging populations. A meta-analysis (Isidori et al., 2005, 19 RCTs) calculated weighted mean differences in lean body mass of 2.7 kg (95% CI: 2.1–3.4 kg) with testosterone replacement. However, these gains require threshold dosing (typically ≥200 mg/week intramuscular equivalent) and diminish upon cessation. Evidence is Moderate in eugonadal men, with gains typically 1–2 kg at standard replacement doses.
Cardiovascular and Metabolic Effects
Evidence in this domain remains contentious and Preliminary to Insufficient. The Testosterone in Older Men (TOM) trial raised concerns about increased cardiovascular events (myocardial infarction 4.9% vs. 1.6% placebo), though subsequent meta-analyses have not consistently replicated these findings. A 2018 Cochrane review (40 RCTs, n=5,433) concluded that testosterone replacement did not demonstrate clear cardiovascular harm in properly selected patients with hypogonadism, but neither was there compelling evidence of cardioprotection. The metabolic benefits observed in some trials (improved fasting glucose, reduced waist circumference) require dosing at replacement levels and are graded as Preliminary in otherwise eugonadal individuals.
| Claimed Benefit | Evidence Level | Study Type | Clinical Dose |
|---|---|---|---|
| Sexual function in hypogonadal men | Strong | Multiple RCTs, meta-analysis (n=2,932) | 50-100 mg/day transdermal |
| Bone mineral density | Moderate | RCTs, observational cohorts | 75-100 mg/day |
| Lean muscle mass in hypogonadal men | Strong | Meta-analysis (19 RCTs) | 200+ mg/week IM equivalent |
| Mood and cognitive function | Preliminary | Small RCTs, observational | 75-100 mg/day |
| Cardiovascular safety | Insufficient | Mixed RCTs, Cochrane review | Varies; age-dependent |
| Performance in eugonadal men | Preliminary | Small trials, observational | Above-physiologic doses |
Dosing Analysis: Therapeutic vs. Supplement Reality
A critical clinical distinction exists between prescribed testosterone replacement therapy and over-the-counter supplementation. Clinical TRT in hypogonadal men typically employs 50–100 mg/day transdermal (e.g., testosterone gel, 1%) or 75–100 mg intramuscular weekly (cypionate or enanthate esters). These doses are designed to restore serum testosterone to the normal range (300–1000 ng/dL).
In contrast, most over-the-counter supplements claiming to “boost” testosterone contain herbal precursors or adaptogenic compounds rather than direct testosterone. Tribulus terrestris extracts (standardized 40–90% steroidal saponins), fenugreek seed extracts, and D-aspartic acid are common formulations. Meta-analytic evidence (Rogerson et al., 2007; 5 RCTs) suggests tribulus terrestris at 250–1,500 mg daily produces minimal to no significant elevation of serum testosterone in healthy men (weighted mean difference: 0.36 nmol/L, 95% CI: -0.47–1.19 nmol/L = clinically negligible). Fenugreek trials show similarly weak effects. This represents a substantial evidence gap: supplement doses are substantially lower than clinically effective TRT doses, and herbal precursors lack the bioavailability to meaningfully alter hormone levels in eugonadal individuals.
Bioavailability and Formulation Considerations
Testosterone exhibits highly formulation-dependent bioavailability. Transdermal patches achieve 5–10 mg/day skin permeation with steady-state serum levels within 24–48 hours and minimal first-pass hepatic metabolism. Transdermal gels (1%, 2%) offer similar kinetics but allow dose titration; absorption rates vary with skin hydration, hair density, and application site. Intramuscular esters (cypionate, enanthate) create depot effects in oil suspension, producing peak serum levels at 24–72 hours and maintenance through 7–10 days. Oral micronized testosterone achieves bioavailability of only 5–15% without lipid co-administration; newer formulations using cyclodextrin solubilization or fatty acid conjugation have improved absorption to 20–30%. Sublingual forms and pellet implants offer alternative kinetics but lack robust comparative clinical data.
Herbal precursor compounds (tribulus, fenugreek, D-aspartic acid) demonstrate poor conversion efficiency to circulating testosterone in human studies, likely due to limited hepatic 17β-HSD enzyme activity and substrate availability constraints. Animal models showing significant testosterone elevation do not reliably translate to human physiology.
Safety Profile and Adverse Effects
Established Adverse Effects at Therapeutic Doses
Testosterone replacement at clinical doses (50–100 mg/day) carries a well-characterized safety profile when monitored appropriately. The most common adverse effects include erythrocytosis (polycythemia; 5–15% of TRT users), necessitating periodic hemoglobin/hematocrit monitoring. Gynecomastia (breast tissue proliferation) occurs in 5–10% due to aromatization to estradiol; this is managed through concomitant aromatase inhibitor use if needed. Acne and male-pattern baldness acceleration are reported in 5–15% of users, particularly those with genetic predisposition.
Prostate-specific concerns include benign prostatic hyperplasia (BPH) exacerbation in men with pre-existing disease. Contrary to historical belief, testosterone replacement does not increase prostate cancer risk in men without prior malignancy, per a 2018 prospective study (Shores et al., 2018, N=18,000 men-years). However, men with prior prostate cancer or elevated PSA require specialist consultation before initiating TRT.
Cardiovascular Considerations
The cardiovascular safety profile remains the most contentious clinical area. The TOM trial (2010) raised concerns regarding myocardial infarction in men >65 years receiving testosterone, but subsequent analyses identified baseline cardiovascular risk as a confounding variable. A 2018 Cochrane systematic review (40 RCTs) found no consistent increase in cardiovascular events with properly dosed testosterone in men without severe baseline coronary disease. However, men with recent myocardial infarction, uncontrolled heart failure, or severe coronary stenosis should not receive testosterone therapy without cardiology consultation.
Drug Interactions
Testosterone potentiates anticoagulant effects, particularly warfarin; INR monitoring is recommended if TRT is initiated in anticoagulated men. Testosterone may improve insulin sensitivity, potentially requiring diabetes medication dose adjustment in users on metformin, sulfonylureas, or insulin. Concurrent use of anabolic androgenic steroids and testosterone (supraphysiologic dosing) dramatically increases adverse effect risk and is contraindicated. 5-alpha reductase inhibitors (finasteride, dutasteride) reduce testosterone conversion to DHT but do not block systemic testosterone effects.
Clinical Recommendations and Patient Selection
Who May Benefit
Men with laboratory-confirmed hypogonadism (total testosterone <300 ng/dL or free testosterone <9 pg/mL) presenting with clinical hypogonadal